You can often get Vyndamax for free through the Vyndamax Co Pay savings program or even through Pfizer Patient Assistance Program, if you are uninsured, have government assistance and meet income requirements of less than 300 percent of the Federal Poverty Level.
You can also contact Pfizer's VyndaLink program or call 1-844-989 PATH to help determine your eligibility and the best options for your situation.
If you have commercial insurance such as through an employer and your prescription is not covered by a federal program, you may be able to get Vyndamax and pay $0 per month using the Co-Pay savings program, you will need to enroll through VynAssist and confirm you are not on a federal program.
Pfizer's patient assistance program via Vyndalink is a program that can also provide free medicine including Vyndamax to eligible patients that are uninsured or have government issued insurance and cannot afford their prescriptions.
To be eligible for Pfizer's patient assistance program, you cannot be commercially insured, your household income must also be at or below 300 percent of the federal poverty level, that is adjusted for your household size and you must also have a valid prescription from a licensed doctor or healthcare provider in the U.S.
Vyndamax typically costs over $21,800.00 per month, although the out-of-pocket cost can also vary significantly based on your health insurance.
Commercially health insured patients may pay as little as $0 per month for Vyndamax through a co-pay savings program, while Medicare patients can have their annual out-of-pocket cost for Vyndamax capped at $2,000.00 for all their Part D medications.
The drug Vyndamax is used for treating cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce hospitalization and death related heart problems.
What Vyndamax does for the heart is stabilize the transthyretin (TTR) protein that helps prevent the TTR protein from misfolding and building up as amyloid fibrils in the heart, which help to prevent death and hospitalization.
Vyndamax is a stabilizer that works by stabilizing the transthyretin (TTR) protein, that helps prevent it from misfolding and building up as amyloid fibrils in organs like the heart.
Vyndamax binds to the TTR protein, which helps keep it's structure intact, which then helps slow down the process of amyloid formation, which is the root cause of diseases like transthyretin mediated amyloidosis.
In contrast, a silencer works by reducing the production of the TTR protein in the first place.
Vyndamax has been on the market since May of 2019.
The U.S. Food and Drug Administration also known as the FDA approved Vyndamax for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Vyndamax was approved around the same time as a similar formulated drug called Vyndaqel, although Pfizer planned to transition any patients to the single capsule Vyndamax, which then became available in the latter half of the year 2019.
The list price for the drug Vyndamax is over $21,800.00 per month, although the out-of-pocket cost can also vary significantly based on your health insurance.
Commercially health insured patients may pay as little as $0 per month for Vyndamax through a co-pay savings program, while Medicare patients can have their annual out-of-pocket cost for Vyndamax capped at $2,000.00 for all their Part D medications.
Vyndamax is a prescription medicine that is used to treat adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.
Although it is not known if Vyndamax is safe and effective in children.
And two out of every five patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (Vyndamax and Vyndaqel; Pfizer) can be expected to die in less than 4 years.
Transthyretin amyloidosis (ATTR-CM) is a disease in which a misfolded protein, transthyretin (TTR), builds up as amyloid deposits in the heart muscle, causing it to become stiff and unable to pump blood effectively.
Symptoms of transthyretin amyloidosis (ATTR-CM) include shortness of breath, swelling in the legs and feet, fatigue, and an irregular heart rate.
Diagnosis for transthyretin amyloidosis (ATTR-CM) involves imaging and sometimes genetic testing, and treatment focuses on slowing disease progression through medication like tafamidis.